Navigation Links
Study Shows Safety of BioPharmX Topical Formulation
Date:12/11/2015

MENLO PARK, Calif., Dec. 11, 2015 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company, announced today that research being presented at ASCB 2015 in San Diego shows its unique formulation of minocycline known as BPX-01 may offer a breakthrough in acne treatment because it can safely deliver the antibiotic to the layer of skin where the condition develops.

Study findings will be presented Monday afternoon at the annual gathering of the American Society of Cell Biology.

Session:  Defining Therapeutic Targets and New Therapeutics 2
Time: 1:30pm to 3:00pm
Location:  ASCB Learning Center, Exhibit Halls D-H

BPX-01 is the first and only stable hydrophilic (non-oil-based) topical gel with fully solubilized minocycline, the antibacterial and anti-inflammatory medicine most commonly prescribed to treat acne because it has a lower resistance rate than other antibiotics.

Topical acne medications available today penetrate the top layer of skin with less effective antibiotics. However, minocycline is generally prescribed as an oral medication due to the lack of availability of effective topical medications. High doses of oral minocycline are associated with various side effects that can discourage compliance.

"Our preliminary findings in animals and in vitro human skin indicate that minocycline delivered by BPX-01 is safely absorbed into the skin, reaching the epidermis and the pilosebaceous unit where acne develops," said Kin F. Chan, Ph.D., executive vice president of research and development at BioPharmX Corporation. "The studies clearly indicate that all doses of BPX-01 were found to be safe and nontoxic for topical use, virtually eliminating risk of undesirable side effects."

The BioPharmX research also found that the hydrophilic BPX-01 formulation distributes evenly, is not sticky and does not occlude or irritate the skin, an advantage in the treatment of acne.

The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting 40 million to 50 million Americans at any given moment. The disease can cause permanent scarring, low self-esteem, depression and anxiety.

About BioPharmX™ Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter ("OTC"), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.

Forward-Looking Statements
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the "safe harbor" created by those section. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding, including with respect to: the success of the commercialization of VI2OLET iodine, the effectiveness of BPX01, the timing with respect to filing an IND and clinical trials for BPX-01, the release of key data for BPX01, the release of key data and the successful completion of multi-site IRB studies for BPX03 and the successful completion of the private placement with Korea Investment Partners Overseas Expansion Platform Fund. These forward-looking statements may be identified by words such as "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements.   These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission.  Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements.  The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

BioPharmX and Violet are registered trademarks of BioPharmX, Inc.

Logo - http://photos.prnewswire.com/prnh/20150711/235327LOGO

 


'/>"/>
SOURCE BioPharmX Corporation
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Advocacy Study Highlights Top Locations for High-Growth Companies
2. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
3. New Study Shows Full Spectrum Endoscopy Procedure Reduces The Miss Rate of Adenomas During Colonoscopy
4. Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak
5. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
6. Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
7. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
8. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
9. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
10. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
11. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2019)... ... January 10, 2019 , ... This week ... lifestyle solutions, will crown the U.S. winner of its annual total-body transformation program, ... Carrara of Palm Beach, Florida; Barbara Lingle of Winterville, North Carolina; Drew Key ...
(Date:1/8/2019)... ... , ... University Hospitals Urology Institute today announced that Irina ... recognizes that Dr. Jaeger has achieved a high level of training and experience ... suffering from symptoms associated with benign prostatic hyperplasia (BPH). , “I’m proud ...
(Date:1/8/2019)... (PRWEB) , ... January 08, 2019 , ... Date aired: ... fatigue and dry eye result from excessive evaporation of the tear film, which is ... and society in general. , So says water researcher Sharon Kleyne, host of the ...
Breaking Medicine Technology:
(Date:1/13/2019)... Pa. (PRWEB) , ... January 12, 2019 , ... ... that it is celebrating its 35th year of service to the community, providing ... proud to be celebrating our 35th anniversary,” said New Vitae co-founder and owner ...
(Date:1/11/2019)... ... 11, 2019 , ... In Partnership with the Smiles for Everyone Foundation ... at its Burleson, TX office on February 9. , Dental services provided ... and extractions . For more information, please visit the Monarch Dental website ...
(Date:1/11/2019)... ... January 11, 2019 , ... Women’s Excellence specializes ... endometriosis tissue, relieve pain, and help restore fertility. , Endometriosis is a disease ... tissue typically grows on the ovaries, fallopian tubes, and the inner lining of ...
(Date:1/10/2019)... , ... January 10, 2019 , ... The Karis Group, ... as its new President & Chief Executive Officer effective immediately. Mr. Jiwa succeeds ... after 9 years of service. The transition was announced as part of an ...
(Date:1/8/2019)... ATLANTA (PRWEB) , ... January 08, 2019 , ... ... Brookhaven, East Point, Morrow, South DeKalb and West End communities have a new ... Centers to their network, effective immediately. , JenCare operates five centers in ...
Breaking Medicine News(10 mins):